BioNTech SE ADR (BNTX): Price and Financial Metrics
BNTX Price/Volume Stats
| Current price | $86.81 | 52-week high | $125.83 |
| Prev. close | $86.17 | 52-week low | $85.21 |
| Day low | $85.63 | Volume | 1,577,800 |
| Day high | $87.59 | Avg. volume | 682,188 |
| 50-day MA | $91.27 | Dividend yield | N/A |
| 200-day MA | $101.40 | Market Cap | 20.64B |
BNTX Stock Price Chart Interactive Chart >
BioNTech SE ADR (BNTX) Company Bio
BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek [2] short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. (Source:Wikipedia)
Latest BNTX News From Around the Web
Below are the latest news stories about BIONTECH SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
This Vaccine Maker’s Stock Is Worth OwningThe vaccine maker has so much cash that it would have appealed to Warren Buffett’s mentor, famed value manager Benjamin Graham. |
15 Undervalued Defensive Stocks For 2024In this article, we discuss the 15 undervalued defensive stocks for 2024. To skip the detailed overview of the market and defensive stocks, go directly to the 5 Undervalued Defensive Stocks For 2024. Defensive stocks are shares of companies that remain relatively stable during economic downturns as opposed to cyclical stocks. Defensive stocks usually outperform […] |
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial CancerDesignation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of anti-tumor activityBreakthrough Therapy designation will allow for an expedited development and regulatory review of BNT323/DB-1303Endometrial or uterine cancer is the second most common gynecologic cancer globally with over 400,000 cases occurring each year MAINZ, Germany and SHANGHAI, China, December |
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights utilized in Comirnaty, BioNTech, and Pfizer Inc's (NYSE: PFE) mRNA COVID-19 vaccine. The ruling represents the first decision on validity in ongoing patent litigation between CureVac and BioNTech in Germany, involving eight CureVac intellectual property rights. Proc |
UPDATE 2-German court quashes CureVac patent after challenge by BioNTechA German court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, in a blow to CureVac's claims for a share in billions of euros in COVID-19 vaccine revenues. CureVac's Nasdaq-listed shares plunged 35% to a record low after the verdict. |
BNTX Price Returns
| 1-mo | -3.54% |
| 3-mo | -11.62% |
| 6-mo | -4.51% |
| 1-year | -28.22% |
| 3-year | -43.33% |
| 5-year | N/A |
| YTD | -17.75% |
| 2023 | -29.74% |
| 2022 | -40.60% |
| 2021 | 216.24% |
| 2020 | 140.61% |
| 2019 | N/A |
Loading social stream, please wait...